Solicitation of Nominations for Appointment to the Lead Exposure and Prevention Advisory Committee, 58585-58586 [2023-18449]
Download as PDF
Federal Register / Vol. 88, No. 165 / Monday, August 28, 2023 / Notices
Purpose: The Clinical Laboratory
Improvement Advisory Committee
(CLIAC) is charged with providing
scientific and technical advice and
guidance to the Secretary, Department
of Health and Human Services; the
Assistant Secretary for Health; the
Director, Centers for Disease Control
and Prevention (CDC); the
Commissioner, Food and Drug
Administration (FDA); and the
Administrator, Centers for Medicare &
Medicaid Services (CMS). The advice
and guidance pertain to general issues
related to improvement in clinical
laboratory quality and laboratory
medicine and specific questions related
to possible revision of the Clinical
Laboratory Improvement Amendments
of 1988 (CLIA) standards. Examples
include providing guidance on studies
designed to improve quality, safety,
effectiveness, efficiency, timeliness,
equity, and patient-centeredness of
laboratory services; revisions to the
standards under which clinical
laboratories are regulated; the impact of
proposed revisions to the standards on
medical and laboratory practice; and the
modification of the standards and
provision of non-regulatory guidelines
to accommodate technological
advances, such as new test methods, the
electronic transmission of laboratory
information, and mechanisms to
improve the integration of public health
and clinical laboratory practices.
Matters To Be Considered: The agenda
will include agency updates from CDC,
CMS, and FDA. Presentations and
CLIAC discussions will focus on the
final report from the CLIA Regulations
Assessment Workgroup, efforts to
address the CLIA top 10 laboratory
deficiencies, standardization of test
result communication, and the role of
the laboratory in antibiotic stewardship.
Agenda items are subject to change as
priorities dictate.
lotter on DSK11XQN23PROD with NOTICES1
Public Participation
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments
pertinent to agenda items.
Oral Public Comment: Public
comment periods for each agenda item
are scheduled immediately prior to the
Committee discussion period for that
item. In general, each individual or
group requesting to present an oral
comment will be limited to a total time
of five minutes (unless otherwise
indicated). Speakers should email
CLIAC@cdc.gov or notify the contact
person above (see FOR FURTHER
INFORMATION CONTACT) at least five
business days prior to the meeting date.
VerDate Sep<11>2014
15:55 Aug 25, 2023
Jkt 259001
Written Public Comment: CLIAC
accepts written comments until the date
of the meeting (unless otherwise stated).
However, it is requested that comments
be submitted at least five business days
prior to the meeting date so that the
comments may be made available to the
Committee for their consideration and
public distribution. Written comments
should be submitted by email to
CLIAC@cdc.gov or to the contact person
above. All written comments will be
included in the meeting minutes posted
on the CLIAC website.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2023–18448 Filed 8–25–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Appointment to the Lead Exposure and
Prevention Advisory Committee
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), within
the Department of Health and Human
Services (HHS), is soliciting
nominations for membership on the
Lead Exposure and Prevention Advisory
Committee (LEPAC). The LEPAC is
composed of 15 members that are
Federal and non-Federal experts in
fields associated with lead screening,
the prevention of lead exposure, and
services for individuals and
communities affected by lead exposure.
DATES: Nominations for membership on
the LEPAC must be received no later
than September 30, 2023. Packages
received after this time will not be
considered for the current membership
cycle.
SUMMARY:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
58585
All nominations should be
emailed to LEPAC@cdc.gov.
FOR FURTHER INFORMATION CONTACT: Paul
Allwood, Ph.D., M.P.H., Designated
Federal Officer, National Center for
Environmental Health, Centers for
Disease Control and Prevention, 4770
Buford Highway, Atlanta, Georgia
30341. Telephone: 770–488–6774;
Email: PAllwood@cdc.gov.
SUPPLEMENTARY INFORMATION:
Nominations are being sought for
individuals with expertise in the fields
of epidemiology, toxicology, mental
health, pediatrics, early childhood
education, special education, diet and
nutrition, and environmental health.
Members may be invited to serve for
three-year terms. Selection of members
is based on candidates’ qualifications to
contribute to the accomplishment of
Lead Exposure and Prevention Advisory
Committee (LEPAC) objectives.
The members of this Committee are
selected by the Secretary of the
Department of Health and Human
Services (HHS). The committee’s
objective is to advise the Secretary, HHS
and the Director, Centers for Disease
Control and Prevention (CDC)/
Administrator, Agency for Toxic
Substances and Disease Registry on a
range of activities to include: (1) review
of Federal programs and services
available to individuals and
communities exposed to lead; (2) review
of the current research on lead exposure
to identify additional research needs; (3)
review of and identification of best
practices, or the need for best practices
regarding lead screening and the
prevention of lead exposure; (4)
identification of effective services,
including services relating to healthcare,
education, and nutrition for individuals
and communities affected by lead
exposure and lead poisoning, including
in consultation with, as appropriate, the
lead exposure registry as established in
Public Law 114–322 section 2203(b) (42
U.S.C. 300j–27); and (5) undertaking of
any other review or activities that the
Secretary determines to be appropriate.
Annually as determined necessary by
the Secretary or as required by Congress,
the committee shall submit a report to
include: (1) an evaluation of the
effectiveness of the Federal programs
and services available to individuals
and communities exposed to lead; (2) an
evaluation of additional lead exposure
research needs; (3) an assessment of any
effective screening methods or best
practices used or developed to prevent
or screen for lead exposure; (4) input
and recommendations for improved
access to effective services relating to
health care, education, or nutrition for
ADDRESSES:
E:\FR\FM\28AUN1.SGM
28AUN1
lotter on DSK11XQN23PROD with NOTICES1
58586
Federal Register / Vol. 88, No. 165 / Monday, August 28, 2023 / Notices
individuals and communities impacted
by lead exposure; and (5) any other
recommendations for communities
affected by lead exposure, as
appropriate.
At least half of the committee will
consist of Federal representatives from a
range of agencies that may include the
Department of Housing and Urban
Development; the Environmental
Protection Agency; the Consumer
Product Safety Commission; the Centers
for Medicare and Medicaid Services; the
Health Resources and Services
Administration; the Food and Drug
Administration (FDA); the U.S.
Department of Agriculture; the
Occupational Safety and Health
Administration; the National Institute of
Environmental Health Sciences; the U.S.
Geological Survey; and such additional
Federal, state, tribal, and local public
and private officials as the Secretary
deems necessary for the committee to
carry out its function. The rest of the
committee will consist of non-Federal
members. Only non-Federal members
are being solicited with this
announcement.
HHS policy stipulates that committee
membership be balanced in terms of
points of view represented and the
committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens
and cannot be full-time employees of
the U.S. Government. Current
participation on Federal workgroups or
prior experience serving on a Federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
advisory committees and multiple
committee memberships. Committee
members are Special Government
Employees, requiring the filing of
financial disclosure reports at the
beginning and annually during their
terms. CDC reviews potential candidates
for LEPAC membership each year and
provides a slate of nominees for
consideration to the Secretary of HHS
for final selection. HHS notifies selected
candidates of their appointment as soon
as the HHS selection process is
completed. Note that the need for
different expertise varies from year to
year and a candidate who is not selected
in one year may be reconsidered in a
subsequent year.
Candidates should submit the
following items:
• Current curriculum vitae, including
complete contact information
VerDate Sep<11>2014
15:55 Aug 25, 2023
Jkt 259001
(telephone numbers, mailing address,
email address).
• At least one letter of
recommendation from person(s) not
employed by HHS. Candidates may
submit letter(s) from current HHS
employees if they wish, but at least one
letter must be submitted by a person not
employed by an HHS agency (e.g., CDC,
National Institutes of Health, FDA).
Nominations may be submitted by the
candidate or by the person/organization
recommending the candidate.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2023–18449 Filed 8–25–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Appointment to the Board of Scientific
Counselors, Center for Preparedness
and Response
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), within
the Department of Health and Human
Services (HHS), is seeking nominations
for membership on the Board of
Scientific Counselors, Center for
Preparedness and Response, (BSC, CPR).
The BSC, CPR consists of 11 experts in
fields associated with business, crisis
leadership, emergency response and
management, informatics, laboratory
science, medicine, mental and
behavioral health, public health law,
public health practice, risk
communication, and social science.
DATES: Nominations for membership on
the BSC, CPR must be received no later
than October 31, 2023. Packages
received after this time will not be
SUMMARY:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
considered for the current membership
cycle.
ADDRESSES: All nominations should be
emailed to BSC-ORR@cdc.gov.
FOR FURTHER INFORMATION CONTACT:
Dometa Ouisley, Public Health Analyst,
Office of Science and Public Health
Practice, Office of Readiness and
Response, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
Mailstop H21–6, Atlanta, Georgia
30329–4027. Telephone: (404) 639–
7450; Email: DOuisley@cdc.gov.
SUPPLEMENTARY INFORMATION:
Nominations are sought for individuals
who have the expertise and
qualifications necessary to contribute to
the accomplishment of the objectives of
the Board of Scientific Counselors,
Center for Preparedness and Response
(BSC, CPR). Nominees will be selected
based on expertise in the fields of
business, crisis leadership, emergency
response and management, informatics,
laboratory science, medicine, mental
and behavioral health, public health
law, public health practice, risk
communication, and social science.
Selection of members is based on
candidates’ qualifications to contribute
to the accomplishment of the BSC, CPR
objectives (https://www.cdc.gov/orr/bsc/
index.htm). Members may be invited to
serve for up to four-year terms.
Department of Health and Human
Services (HHS) policy stipulates that
committee membership be balanced in
terms of points of view represented and
the committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens
and cannot be full-time employees of
the U.S. Government. Current
participation on federal workgroups or
prior experience serving on a federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
advisory committees and multiple
committee memberships.
Board members are Special
Government Employees, requiring the
filing of financial disclosure reports at
the beginning of and annually during
their terms. The Centers for Disease
Control and Prevention (CDC) reviews
potential candidates for BSC, CPR
membership each year and provides a
slate of nominees for consideration to
the Secretary of HHS for final selection.
HHS notifies selected candidates of
their appointment near the start of the
term in October 2024, or as soon as the
HHS selection process is completed.
E:\FR\FM\28AUN1.SGM
28AUN1
Agencies
[Federal Register Volume 88, Number 165 (Monday, August 28, 2023)]
[Notices]
[Pages 58585-58586]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18449]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Solicitation of Nominations for Appointment to the Lead Exposure
and Prevention Advisory Committee
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), within
the Department of Health and Human Services (HHS), is soliciting
nominations for membership on the Lead Exposure and Prevention Advisory
Committee (LEPAC). The LEPAC is composed of 15 members that are Federal
and non-Federal experts in fields associated with lead screening, the
prevention of lead exposure, and services for individuals and
communities affected by lead exposure.
DATES: Nominations for membership on the LEPAC must be received no
later than September 30, 2023. Packages received after this time will
not be considered for the current membership cycle.
ADDRESSES: All nominations should be emailed to [email protected].
FOR FURTHER INFORMATION CONTACT: Paul Allwood, Ph.D., M.P.H.,
Designated Federal Officer, National Center for Environmental Health,
Centers for Disease Control and Prevention, 4770 Buford Highway,
Atlanta, Georgia 30341. Telephone: 770-488-6774; Email:
[email protected].
SUPPLEMENTARY INFORMATION: Nominations are being sought for
individuals with expertise in the fields of epidemiology, toxicology,
mental health, pediatrics, early childhood education, special
education, diet and nutrition, and environmental health. Members may be
invited to serve for three-year terms. Selection of members is based on
candidates' qualifications to contribute to the accomplishment of Lead
Exposure and Prevention Advisory Committee (LEPAC) objectives.
The members of this Committee are selected by the Secretary of the
Department of Health and Human Services (HHS). The committee's
objective is to advise the Secretary, HHS and the Director, Centers for
Disease Control and Prevention (CDC)/Administrator, Agency for Toxic
Substances and Disease Registry on a range of activities to include:
(1) review of Federal programs and services available to individuals
and communities exposed to lead; (2) review of the current research on
lead exposure to identify additional research needs; (3) review of and
identification of best practices, or the need for best practices
regarding lead screening and the prevention of lead exposure; (4)
identification of effective services, including services relating to
healthcare, education, and nutrition for individuals and communities
affected by lead exposure and lead poisoning, including in consultation
with, as appropriate, the lead exposure registry as established in
Public Law 114-322 section 2203(b) (42 U.S.C. 300j-27); and (5)
undertaking of any other review or activities that the Secretary
determines to be appropriate.
Annually as determined necessary by the Secretary or as required by
Congress, the committee shall submit a report to include: (1) an
evaluation of the effectiveness of the Federal programs and services
available to individuals and communities exposed to lead; (2) an
evaluation of additional lead exposure research needs; (3) an
assessment of any effective screening methods or best practices used or
developed to prevent or screen for lead exposure; (4) input and
recommendations for improved access to effective services relating to
health care, education, or nutrition for
[[Page 58586]]
individuals and communities impacted by lead exposure; and (5) any
other recommendations for communities affected by lead exposure, as
appropriate.
At least half of the committee will consist of Federal
representatives from a range of agencies that may include the
Department of Housing and Urban Development; the Environmental
Protection Agency; the Consumer Product Safety Commission; the Centers
for Medicare and Medicaid Services; the Health Resources and Services
Administration; the Food and Drug Administration (FDA); the U.S.
Department of Agriculture; the Occupational Safety and Health
Administration; the National Institute of Environmental Health
Sciences; the U.S. Geological Survey; and such additional Federal,
state, tribal, and local public and private officials as the Secretary
deems necessary for the committee to carry out its function. The rest
of the committee will consist of non-Federal members. Only non-Federal
members are being solicited with this announcement.
HHS policy stipulates that committee membership be balanced in
terms of points of view represented and the committee's function.
Appointments shall be made without discrimination on the basis of age,
race, ethnicity, gender, sexual orientation, gender identity, HIV
status, disability, and cultural, religious, or socioeconomic status.
Nominees must be U.S. citizens and cannot be full-time employees of the
U.S. Government. Current participation on Federal workgroups or prior
experience serving on a Federal advisory committee does not disqualify
a candidate; however, HHS policy is to avoid excessive individual
service on advisory committees and multiple committee memberships.
Committee members are Special Government Employees, requiring the
filing of financial disclosure reports at the beginning and annually
during their terms. CDC reviews potential candidates for LEPAC
membership each year and provides a slate of nominees for consideration
to the Secretary of HHS for final selection. HHS notifies selected
candidates of their appointment as soon as the HHS selection process is
completed. Note that the need for different expertise varies from year
to year and a candidate who is not selected in one year may be
reconsidered in a subsequent year.
Candidates should submit the following items:
Current curriculum vitae, including complete contact
information (telephone numbers, mailing address, email address).
At least one letter of recommendation from person(s) not
employed by HHS. Candidates may submit letter(s) from current HHS
employees if they wish, but at least one letter must be submitted by a
person not employed by an HHS agency (e.g., CDC, National Institutes of
Health, FDA).
Nominations may be submitted by the candidate or by the person/
organization recommending the candidate.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-18449 Filed 8-25-23; 8:45 am]
BILLING CODE 4163-18-P